Forbion is a dedicated life sciences venture capital firm with offices in Naarden, Munich, and Cambridge. It focuses on investing in life sciences companies that are developing innovative medicines and medical technologies to improve patient care. The firm manages over €1.7 billion of investments and has a team of experienced investment professionals and scientists.

Forbion was born out of ABN AMRO Capital Life Sciences in 2000. Six years later, we transitioned to Forbion Capital Partners. Today, to emphasize our value-add beyond merely providing capital, we are simply known as Forbion. For more than two decades, our investment team has built an impressive track record of sourcing, building and guiding life-sciences companies resulting in many breakthrough therapies and valuable exits.

Forbion currently manages over €2.3 bn across ten funds. As of October 2022, Forbion holds 43 active portfolio companies bringing its investments to 95 companies to date with 46 employees.

Forbion’s investors include the European Investment Fund (EIF), notably through its European Recovery Programme (ERP), LfA, the Dutch Venture Initiative (DVI) and AMUF facilities, and the Kreditanstalt für Wiederaufbau (KFW) through the ERP – Venture Capital Fondsfinanzierung facility.

Bluebird Bio

Replimune Group

UniQure

VectivBio

Dyne Therapeutics

Exosome Diagnostics

Acadia Pharmaceuticals Inc.

Achilles Therapeutics

Argos Therapeutics

Gyroscope Therapeutics

Hookipa Pharma

Insmed

Forbion

It is quite the week for us at Forbion. Today we are pleased to announce our participation as a new investor in Capstan Therapeutics' oversubscribed $175M Series B financing round. Capstan is dedicated to advancing in vivo cell reprogramming through #RNA delivery using targeted lipid nanoparticles.

This round, led by RA Capital Management, saw additional investments from Johnson & Johnson Innovation, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments , along with participation from Capstan's existing investors.

We are proud to support Capstan's groundbreaking work, which marks the tenth investment from our Growth Opportunities II Fund. Additionally, our General Partner, Nanna Lüneborg, PhD, MBA, joins Capstan's Board of Directors. Exciting times ahead! Click on the link below to learn more. #LifeSciences #VentureCapital #Investment #Innovation #biotech #financingnews Melanie de Almeida Mathias Vinther Tim Lohoff, Ph.D.

Forbion is proud to announce our latest milestone in supporting groundbreaking advancements in the life sciences industry. We are thrilled to co-lead a $157 million Series B financing round in Engrail Therapeutics alongside F-Prime Capital Partners and Norwest Venture Partners . Engrail Therapeutics is at the forefront of developing transformative therapies for conditions such as anxiety disorders, depression, PTSD, and rare neurodegenerative diseases. Their lead asset, ENX-102, currently in phase II development for generalized anxiety disorder, holds immense promise in reshaping treatment paradigms and improving patient outcomes. The proceeds from this financing round will support Engrail's pipeline through critical stages of clinical development, bringing hope to millions of individuals grappling with these debilitating conditions. This achievement also underscores the strength of Forbion's Growth Opportunities II Fund, which raised €600 million in 2023. Engrail marks the ninth investment from this fund, reflecting our dedication to supporting European late-stage biopharma companies pioneering novel therapies in areas of profound medical need. Jasper Bos Melanie de Almeida Marc-Olivier Turgeon #LifeSciences #Biopharma #Innovation #Healthcare #Investment #EngrailTherapeutics 

Online registration for EBD Group's Bio-Europe Spring closes tomorrow Friday 15 March. Join the Forbion team from March 18-20 for this biotech springtime partnering event. Marc-Olivier Turgeon, Vanessa Carle, and Alice Vickers, will be in in Barcelona. Click the link below to learn more. #BioEuropeSpring #Biotech #Barcelona #ForbionTeam #Meettheteam #conference #biotech #lifesciences 


Forbion portfolio company Prilenia - dedicated to combating neurodegenerative diseases and neurodevelopmental disorders - has announced its plans to submit a Marketing Authorization Application (MAA) for pridopidine, a promising therapeutic, designed to slow the progression of Huntington's disease (HD) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). This decision follows positive pre-submission meetings with regulatory authorities in the European Union. Submission is planned for mid-2024.

Stay tuned for further updates as Prilenia continues its remarkable progress in reshaping the future of neurodegenerative disease treatment. Click the link below to read the official company press release. #Prilenia #NeurodegenerativeDiseases #Innovation #lifesciences #Biotechnology #HuntingtonsDisease #ClinicalResearch #MedicalInnovation Geert-Jan Mulder Rogier Rooswinkel


Are you ready for a dynamic career in life sciences venture capital? We are offering a unique 6-9 month fellowship with us in Naarden, The Netherlands. You will have the opportunity to dive into company due diligence activities, interact with investors, bankers, & advisers, develop skills in scientific, clinical, regulatory, commercial, & financial analyses and most importantly, learn from an international team with extensive life sciences experience! Apply now for a chance to work on deal flow management, investment due diligence, and contribute to special projects. Click on the link below to learn how to apply. 
#LifeSciences #VentureCapital #CareerOpportunity #Vacancy #Application #fellowship #career #biotech #opportunity #forbion 


COM:FORBION

Forbion

Analysis Not Available